- £15 million maintenance contract awarded to Bilfinger for a biopharma manufacturing facility in Scotland
- Contract commenced 1 May 2026 with an initial three-year term and two one-year extension options
- Around 60 skilled tradespeople will transfer from the incumbent provider to Bilfinger
- Scope covers electrical, instrumentation, access, insulation, painting, and shutdown/project support in a GMP-regulated site producing essential medicines
Contract overview
Bilfinger has been awarded a £15 million (~€17 million) maintenance contract at a biopharma manufacturing facility in Scotland; the contract started on 1 May 2026 and has an initial three-year term with two optional one-year extensions.
Workforce transfer
As part of the transition, around 60 skilled tradespeople will transfer from the incumbent provider to Bilfinger to maintain continuity of site knowledge and operations.
Scope of services
The agreement covers integrated maintenance services including electrical, instrumentation, access, insulation and painting, plus shutdown and project support.
Operational environment
Services will be delivered within a GMP-regulated biopharma production site supporting essential medicines, with focus on asset integrity, operational availability and regulatory compliance.
